东华软件(002065 .SZ):子公司中标1.99亿元项目
格隆汇 12 月 7日丨东华软件(002065 .SZ)公布,近日,公司全资子公司北京东华合创科技有限公司收到招标代理机构福建省天海招标有限公司(受福建省数字福建云计算运营有限公司的委托)发出的《中标通知书》,中标项目金额为人民币1.99亿元,项目名称及内容:东南健康医疗大数据中心IT基础设施建设一期工艺施工总集成项目。
此次中标符合公司业务战略规划,代表公司在智慧城市的健康医疗大数据方向得到客户及评审专家的高度认可,展现了公司在智慧城市领域的综合技术实力和行业竞争优势,本项目的实施将对公司的未来业务发展及经营业绩提升产生积极影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.